Orbis Medicines ApS: Financial statements 2023
CVR: 42715646
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Orbis Medicines ApS (CVR 42715646) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -25,595,747 and a net result of DKK -17,637,755. Equity in the 2023 report amounted to DKK 68,949,917. The solvency ratio was 98%.
- Gross Profit
- DKK -25,595,747
- Profit/Loss
- DKK -17,637,755
- Equity
- DKK 68,949,917
- Total Assets
- DKK 70,365,732
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Orbis Medicines ApS has published its interim report for the period September 28, 2021 to December 31, 2022.
About Orbis Medicines ApS
Orbis Medicines ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Morten Døssing. The board consists of Goran Mikael Dolsten (chair), Alonso Ricardo Rodriguez, Edward Timothy Mathers and Marco Boorsma. The company is owned by Novo Holdings A/S, Forbion Ventures Fund VI Coöperatief U.A. and GF 2022 Global VC S.á r.l.. The company has 32 employees (2026). In 2025, the company reported a gross profit of DKK -114,117,791 and a net result of DKK -136,526,045 compared with DKK -37,020,933 the year before. Equity in the 2025 report amounted to DKK 287,462,567.